CureVac (NASDAQ:CVAC) shares are trading higher after the company reported its vaccine candidate, CV2CoV, demonstrated high immunogenicity against virus variants in a preclinical study.
CureVac's stock has been rising Thursday, up 7.15% to a price of $99.34. Thursday the stock has been traded at a volume of 636.39 thousand, about 52.18% of its recent 30-day volume average of 1.22 million.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The moving average price of the stock over the past 50 days was $97.48 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $151.8 and as low as $43.0.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.